PRME
Prime Medicine Inc
$
3.785
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
3.790
Open
3.670
VWAP
3.65
Vol
3.59M
Mkt Cap
509.36M
Low
3.500
Amount
13.10M
EV/EBITDA(TTM)
--
Total Shares
120.03M
EV
--
EV/OCF(TTM)
--
P/S(TTM)
97.42
Prime Medicine, Inc. is a biotechnology company engaged in creating and delivering gene editing therapies to patients. It deploys its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated one-time curative genetic therapies. It is advancing a set of high-value programs across its core areas of focus (hematology, immunology and oncology, liver, and lung). These include ex vivo hematopoietic stem cell (HSC) programs for the treatment of p47phox chronic granulomatous disease CGD and X-linked CGD; a lipid nanoparticle (LNP) Prime Editor for the treatment of Wilson’s Disease; a LNP or adeno-associated virus Prime Editors for the treatment of cystic fibrosis; and ex vivo T-cell therapies. PM359, its product candidate within its hematology, immunology and oncology area of focus, targets the p47phox variant of CGD. Its PM577 comprises a Prime Editor encapsulated as RNA cargo in a liver-targeted LNP.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q1
FY2025Q4
FY2025Q3
4.61M
+110.95%
-0.220
-45%
2.79M
+1234.88%
-0.182
-41.4%
--
--
-0.235
-46.59%
Estimates Revision
The market is revising Downward the revenue expectations for Prime Medicine, Inc. (PRME) for FY2025, with the revenue forecasts being adjusted by -23.68% over the past three months. During the same period, the stock price has changed by 182.46%.
Revenue Estimates for FY2025
Revise Downward
-23.68%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+1.32%
In Past 3 Month
Stock Price
Go Up
+182.46%
In Past 3 Month
9 Analyst Rating
66.45% Upside
Wall Street analysts forecast PRME stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PRME is 6.30 USD with a low forecast of 1.50 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
4 Hold
0 Sell
Moderate Buy
66.45% Upside
Current: 3.785
Low
1.50
Averages
6.30
High
10.00
66.45% Upside
Current: 3.785
Low
1.50
Averages
6.30
High
10.00
Citi
Buy
to
Neutral
downgrade
$10
2025-05-26
Reason
Citi
Price Target
$10
2025-05-26
downgrade
Buy
to
Neutral
Reason
Citi downgraded Prime Medicine to Neutral from Buy with a price target of $1.50, down from $10. The shares are trading near cash, reflecting the market's uncertainty on the company's path to potential value inflection, the analyst tells investors in a research note. The firm says Prime's cash runway supports operations only into the first half of 2026 after implementing cost-cutting measures, which is well short of management's guidance of initial in-vivo clinical data for Wilson's and Alpha-1 antitrypsin deficiency in 2027.
Citizens JMP
Silvan Tuerkcan
Outperform
to
Outperform
downgrade
$10 -> $6
2025-05-20
Reason
Citizens JMP
Silvan Tuerkcan
Price Target
$10 -> $6
2025-05-20
downgrade
Outperform
to
Outperform
Reason
Citizens JMP analyst Silvan Tuerkcan lowered the firm's price target on Prime Medicine to $6 from $10 and keeps an Outperform rating on the shares. Prime Medicine is focusing its efforts on high-value in-vivo opportunities, Wilson's disease and Alpha-1 Antitrypsin Deficiency, and is making changes to management and the company, with Allain Reine taking over the CEO role from Keith Gottesdiener, who will remain as a consultant, while Jeff Marrazzo was appointed Executive Chair, the analyst tells investors in a research note. Citizens views the removal of Chronic Granulomatous Disease as a sensible decision, given the backdrop of ex-vivo cell therapy launches, large opex requirements, and the small patient population.
H.C. Wainwright
Arthur He
Buy -> Neutral
downgrade
2025-05-20
Reason
H.C. Wainwright
Arthur He
Price Target
2025-05-20
downgrade
Buy -> Neutral
Reason
H.C. Wainwright analyst Arthur He downgraded Prime Medicine to Neutral from Buy without a price target. The company decided to discontinue the development of PM359 for the treatment of chronic granulomatous disease as well as the X-linked CGD program, while focusing on its in vivo liver franchise including PM577 for Wilson's Disease and recently unveiled alpha-1 antitrypsin deficiency program, the analyst tells investors in a research note. The firm is surprised by Prime's decision and now sees financial and legal uncertainties as well as a lack of catalysts for the shares.
Chardan
Geulah Livshits
Buy
downgrade
$16 -> $12
2025-05-19
Reason
Chardan
Geulah Livshits
Price Target
$16 -> $12
2025-05-19
downgrade
Buy
Reason
Chardan analyst Geulah Livshits lowered the firm's price target on Prime Medicine (PRME) to $12 from $16 and keeps a Buy rating on the shares after Prime reported its CGD prime editing asset PM359 had shown impressive activity in the first treated patient, but that the company would be deprioritizing its CGD franchise to focus on execution in its in vivo liver-directed prime editing programs in Wilson's disease and alpha-1 antitrypsin deficiency. The firm, which notes that the move echoes Editas Medicine's (EDIT) shift to in vivo announced last year, viewed PM359 as "an important step for clinical proof of concept for prime editing" with a high probability of technical success, but as "a comparatively modest component of our valuation," the analyst tells investors. With clinical readouts on prioritized programs not expected until 2027, the firm now looks to business development activity for "opportunities for value inflection," the analyst added.
JPMorgan
Overweight -> Neutral
downgrade
2025-05-19
Reason
JPMorgan
Price Target
2025-05-19
downgrade
Overweight -> Neutral
Reason
JPMorgan downgraded Prime Medicine to Neutral from Overweight without a price target. The company announced that it is deprioritizing its chronic granulomatous disease program, turning over leadership and reducing headcount, the analyst tells investors in a research note. The firm says that while the strategic prioritization looks "prudent," Prime's resulting clinical catalyst outlook gets pushed back beyond its current first half of 2026 cash runway. With net cash $1 per share, the stock will like be range bound pending better visibility on development timelines and reach within key pipeline programs, contends JPMorgan.
Chardan Capital
Geulah Livshits
Strong Buy
Maintains
$15 → $16
2025-03-20
Reason
Chardan Capital
Geulah Livshits
Price Target
$15 → $16
2025-03-20
Maintains
Strong Buy
Reason
Chardan analyst Geulah Livshits raised the firm's price target on Prime Medicine to $16 from $15 and keeps a Buy rating on the shares. The firm says that on March 18th, Prime Medicine, a Chardan Biotech Top Pick for 2025, disclosed an in vivo prime editing program for alpha-1 antitrypsin deficiency that is tracking toward IND/CTA filing in mid-2026, giving the company a foothold in a not-so-rare disease market. Chardan updated its model to break out this indication from the company's broader early-stage in vivo editing efforts. Importantly, while newly disclosed, the program is not a new addition, and is included within the company's cash runway guidance, it adds.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Prime Medicine Inc (PRME.O) is -3.96, compared to its 5-year average forward P/E of -4.94. For a more detailed relative valuation and DCF analysis to assess Prime Medicine Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-4.94
Current PE
-3.96
Overvalued PE
-2.01
Undervalued PE
-7.87
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-4.05
Current EV/EBITDA
-4.11
Overvalued EV/EBITDA
-0.55
Undervalued EV/EBITDA
-7.55
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
151.04
Current PS
30.08
Overvalued PS
369.49
Undervalued PS
-67.42
Financials
Annual
Quarterly
FY2025Q2
1.12M
Total Revenue
FY2025Q2
YoY :
-4.12%
-53.38M
Operating Profit
FY2025Q2
YoY :
-4.95%
-52.59M
Net Income after Tax
FY2025Q2
YoY :
-10.87%
-0.41
EPS - Diluted
FY2025Q2
YoY :
-9.30%
-42.98M
Free Cash Flow
FY2025Q2
YoY :
0.00%
100.00
Gross Profit Margin - %
FY2025Q2
-2.16K
FCF Margin - %
FY2025Q2
YoY :
-72.42%
-4.72K
Net Margin - %
Trading Trends
Insider
Insiders areBuying! The selling amount has increased 18302.86% over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
7
30.2M
USD
Months
3-6
3
283.9K
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders areBuying! The selling amount has increased 18302.86% over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
7
30.2M
USD
Months
3-6
3
283.9K
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
PRME News & Events
Events Timeline
2025-08-07 (ET)
2025-08-07
08:05:00
Prime Medicine reports Q2 EPS (41c), consensus (34c)
2025-07-30 (ET)
2025-07-30
23:07:50
Prime Medicine 38M share Spot Secondary priced at $3.30
2025-07-30
16:05:38
Prime Medicine announces common stock offering, no amount given
Sign Up For More Events
Sign Up For More Events
News
4.0
08-08BenzingaChardan Capital Maintains Buy on Prime Medicine, Lowers Price Target to $10
5.0
08-01TipRanksCathie Wood Buys $69M Worth of Figma Stock on Blockbuster IPO Debut
9.5
07-31BenzingaAlign Technology Posts Downbeat Earnings, Joins Confluent,FormFactor And Other Big Stocks Moving Lower In Thursday Pre-Market Session
Sign Up For More News
People Also Watch
HOUS
Anywhere Real Estate Inc
5.040
USD
-0.79%
BMRC
Bank of Marin Bancorp
22.190
USD
+1.46%
HBCP
Home Bancorp Inc
50.620
USD
+1.12%
KOD
Kodiak Sciences Inc
7.900
USD
-3.66%
TERN
Terns Pharmaceuticals Inc
6.080
USD
+7.80%
ZEUS
Olympic Steel Inc
31.130
USD
+1.37%
NYXH
Nyxoah SA
7.420
USD
-1.07%
ILLR
Triller Group Inc
0.500
USD
-2.15%
CCIX
Churchill Capital Corp IX
10.540
USD
-0.09%
JMIA
Jumia Technologies AG
5.780
USD
-0.69%
FAQ
What is Prime Medicine Inc (PRME) stock price today?
The current price of PRME is 3.785 USD — it has increased 2.85 % in the last trading day.
What is Prime Medicine Inc (PRME)'s business?
What is the price predicton of PRME Stock?
What is Prime Medicine Inc (PRME)'s revenue for the last quarter?
What is Prime Medicine Inc (PRME)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Prime Medicine Inc (PRME)'s fundamentals?
How many employees does Prime Medicine Inc (PRME). have?